Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

About one in eight adults say they are taking a GLP-1 receptor agonist as a treatment for obesity, diabetes or another ...

Paul Edison, MD, PhD, of Imperial College London, who wasn't involved with the studies, called the findings "an undeniable ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

BMS’ Patient Connect platform will enable customers to purchase Sotyktu for more than 80% less than the drug’s current list price. Image credit: Rosemarie Mosteller via Shutterstock.com. Bristol Myers ...

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after reporting positive results in a phase 3 trial. Full data from the ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Bristol Myers Squibb stock (NYSE: BMY) has risen by 7% this year, outperforming the S&P 500 which has fallen by 1%. BMS’s robust Q4 performance has contributed to its positive momentum. Although new U ...